No connection

Search Results

BIAF vs XTLB

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
XTLB
XTL Biopharmaceuticals Ltd.
BEARISH
Price
$2.44
Market Cap
$5.8M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
XTLB
--
Forward P/E
BIAF
-2.25
XTLB
--
P/B Ratio
BIAF
0.52
XTLB
--
P/S Ratio
BIAF
0.9
XTLB
5.98
EV/EBITDA
BIAF
0.09
XTLB
--

Profitability

Gross Margin
BIAF
27.86%
XTLB
-232.85%
Operating Margin
BIAF
-158.56%
XTLB
-853.58%
Profit Margin
BIAF
-217.5%
XTLB
0.0%
ROE
BIAF
-245.18%
XTLB
-577.13%
ROA
BIAF
-71.71%
XTLB
-240.56%

Growth

Revenue Growth
BIAF
-38.5%
XTLB
--
Earnings Growth
BIAF
--
XTLB
--

Financial Health

Debt/Equity
BIAF
0.08
XTLB
--
Current Ratio
BIAF
3.65
XTLB
0.7
Quick Ratio
BIAF
3.44
XTLB
0.46

Dividends

Dividend Yield
BIAF
--
XTLB
--
Payout Ratio
BIAF
0.0%
XTLB
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
XTLB BEARISH

XTLB exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a complete lack of positive fundamental momentum. The company suffers from catastrophic profitability metrics, including an operating margin of -853.58% and a negative gross margin of -232.85%, indicating a fundamentally broken cost structure. Liquidity is critical with a current ratio of 0.70 and a quick ratio of 0.46, suggesting an inability to meet short-term obligations. Combined with a 0/100 technical trend and an 81.5% decline over five years, the stock presents an extremely high-risk profile.

Strengths
Low current price relative to 52-week high ($10.28)
Positive EPS surprise recorded in historical 2015 data
Micro-cap status allows for high volatility spikes
Risks
Severe liquidity crisis (Current Ratio 0.70)
Extreme negative margins (Operating Margin -853.58%)
Chronic value destruction (5Y Change -81.5%)

Compare Another Pair

BIAF vs XTLB: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and XTL Biopharmaceuticals Ltd. (XTLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile